ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids(Dana-Farber Cancer Institute), Javier Pinilla Ibarz(Moffitt Cancer Center), Michael Maris(Sarah Cannon), Enrique Granados, John M. Pagel(University of Washington), Justyna Kanska, Saad S. Kenderian(Mayo Clinic in Arizona), Nancy L. Bartlett(Washington University in St. Louis), Behzad Kharabi Masouleh(Erytech Pharma (France)), Paolo Ghia(Vita-Salute San Raffaele University), Yan Zheng, Wangshu Zhang, Ian W. Flinn(Tennessee Oncology), Michael Byrne(Vanderbilt University), Brian T. Hill(Cleveland Clinic)
Cited by 12
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k